BACKGROUND: We present data on Pap test results and HPV prevalence from the HPV Sentinel Surveillance project, a multiyear surveillance project enrolling women from a diverse set of 26 clinics throughout the US from 2003 to 2005. We use mathematical modeling to illustrate the potential timing and magnitude of decreases in Pap test abnormalities in sexually transmitted disease (STD), family planning, and primary care clinics in the US as a result of HPV vaccination. METHODS: The probability of an abnormal Pap result was based on three factors: (1) infection with HPV 16/18, or both; (2) infection with high-risk HPV types other than HPV 16/18; and (3) infection with HPV 6/11, or both. We estimated the relative reduction in the probability of an abnormal Pap result over the first 25 years of a female-only, quadrivalent HPV vaccination program, compared to a scenario of no HPV vaccination in which the probability of abnormal Pap results was assumed constant. RESULTS: The probability of an abnormal Pap result ranged from 7.0% for the lowest risk group (those without any high-risk HPV types and without HPV 6/11) to 45.2% for the highest risk group (those with HPV 16/18 and at least one other high-risk HPV type). Estimated reductions in abnormal Pap results among women in the 21- to 29-year age group were 0.8%, 10.2%, and 11.3% in years 5, 15, and 25 of the vaccine program respectively, in the lower vaccine coverage scenario, and 7.4%, 21.4%, and 22.2%, respectively, in the higher coverage scenario. CONCLUSIONS: Our results suggest that HPV vaccination will have a discernable impact on the probability of Pap abnormalities, but the timing and magnitude of the reduction will depend substantially on vaccine coverage and the degree of cross-protection against high risk HPV types other than HPV 16/18. Published by Elsevier Ltd.
BACKGROUND: We present data on Pap test results and HPV prevalence from the HPV Sentinel Surveillance project, a multiyear surveillance project enrolling women from a diverse set of 26 clinics throughout the US from 2003 to 2005. We use mathematical modeling to illustrate the potential timing and magnitude of decreases in Pap test abnormalities in sexually transmitted disease (STD), family planning, and primary care clinics in the US as a result of HPV vaccination. METHODS: The probability of an abnormal Pap result was based on three factors: (1) infection with HPV 16/18, or both; (2) infection with high-risk HPV types other than HPV 16/18; and (3) infection with HPV 6/11, or both. We estimated the relative reduction in the probability of an abnormal Pap result over the first 25 years of a female-only, quadrivalent HPV vaccination program, compared to a scenario of no HPV vaccination in which the probability of abnormal Pap results was assumed constant. RESULTS: The probability of an abnormal Pap result ranged from 7.0% for the lowest risk group (those without any high-risk HPV types and without HPV 6/11) to 45.2% for the highest risk group (those with HPV 16/18 and at least one other high-risk HPV type). Estimated reductions in abnormal Pap results among women in the 21- to 29-year age group were 0.8%, 10.2%, and 11.3% in years 5, 15, and 25 of the vaccine program respectively, in the lower vaccine coverage scenario, and 7.4%, 21.4%, and 22.2%, respectively, in the higher coverage scenario. CONCLUSIONS: Our results suggest that HPV vaccination will have a discernable impact on the probability of Pap abnormalities, but the timing and magnitude of the reduction will depend substantially on vaccine coverage and the degree of cross-protection against high risk HPV types other than HPV 16/18. Published by Elsevier Ltd.
Authors: Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers Journal: Am J Clin Pathol Date: 2012-04 Impact factor: 2.493
Authors: Lauri E Markowitz; Susan Hariri; Elizabeth R Unger; Mona Saraiya; S Deblina Datta; Eileen F Dunne Journal: Vaccine Date: 2010-02-25 Impact factor: 3.641
Authors: N H Gaffga; E W Flagg; H S Weinstock; J C Shlay; K G Ghanem; L A Koutsky; P R Kerndt; K K Hsu; E R Unger; S D Datta Journal: Vaccine Date: 2012-01-18 Impact factor: 3.641
Authors: Barbara Romanowski; Tino F Schwarz; Linda M Ferguson; Klaus Peters; Marc Dionne; Karin Schulze; Brian Ramjattan; Peter Hillemanns; Grégory Catteau; Kurt Dobbelaere; Anne Schuind; Dominique Descamps Journal: Hum Vaccin Date: 2011-12-01
Authors: X Castellsagué; N Muñoz; P Pitisuttithum; D Ferris; J Monsonego; K Ault; J Luna; E Myers; S Mallary; O M Bautista; J Bryan; S Vuocolo; R M Haupt; A Saah Journal: Br J Cancer Date: 2011-05-31 Impact factor: 7.640
Authors: Aimée R Kreimer; Ana Cecilia Rodriguez; Allan Hildesheim; Rolando Herrero; Carolina Porras; Mark Schiffman; Paula González; Diane Solomon; Silvia Jiménez; John T Schiller; Douglas R Lowy; Wim Quint; Mark E Sherman; John Schussler; Sholom Wacholder Journal: J Natl Cancer Inst Date: 2011-09-09 Impact factor: 13.506
Authors: Jennifer C Spencer; Noel T Brewer; Justin G Trogdon; Morris Weinberger; Tamera Coyne-Beasley; Stephanie B Wheeler Journal: Pediatrics Date: 2020-11-16 Impact factor: 7.124
Authors: Jong Kim; Christopher Bell; Maggie Sun; Gordon Kliewer; Linan Xu; Maria McInerney; Lawrence W Svenson; Huiming Yang Journal: CMAJ Date: 2016-07-04 Impact factor: 8.262